The combination of duvelisib, a PI3K-δ,γ inhibitor, and romidepsin is highly active in relapsed/refractory peripheral T-cell lymphoma with low rates of transaminitis: Results of parallel multicenter, phase 1 combination studies with expansion cohorts Meeting Abstract


Authors: Horwitz, S. M.; Moskowitz, A. J.; Jacobsen, E. D.; Mehta-Shah, N.; Khodadoust, M. S.; Fisher, D. C.; Myskowski, P.; Wang, E. B. K.; Tawa, M.; Davey, T.; Blouin, W.; Hancock, H.; Ganesan, N.; Galasso, N.; Marzouk, E.; Bahgat, A.; Jester, H.; Fong, S.; Butt, A.; Dogan, A.; Kim, Y. H.; Weinstock, D. M.
Abstract Title: The combination of duvelisib, a PI3K-δ,γ inhibitor, and romidepsin is highly active in relapsed/refractory peripheral T-cell lymphoma with low rates of transaminitis: Results of parallel multicenter, phase 1 combination studies with expansion cohorts
Meeting Title: 60th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 132
Issue: Suppl. 1
Meeting Dates: 2018 Dec 1-4
Meeting Location: San Diego, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2018-11-29
Language: English
ACCESSION: WOS:000454837602061
PROVIDER: wos
DOI: 10.1182/blood-2018-99-115241
Notes: Meeting Abstract: 683 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Steven M Horwitz
    645 Horwitz
  2. Alison Moskowitz
    339 Moskowitz
  3. Patricia Myskowski
    216 Myskowski
  4. Ahmet Dogan
    455 Dogan
  5. Natasha   Galasso
    40 Galasso
  6. Theresa Davey
    22 Davey
  7. Nivetha Ganesan
    48 Ganesan
  8. Helen Hancock
    21 Hancock
  9. William Blouin
    5 Blouin
  10. Alexandra Bahgat
    3 Bahgat